JP2023554119A - 安定化されたｔｃｒコンストラクト及び使用方法 - Google Patents

安定化されたｔｃｒコンストラクト及び使用方法 Download PDF

Info

Publication number
JP2023554119A
JP2023554119A JP2023537488A JP2023537488A JP2023554119A JP 2023554119 A JP2023554119 A JP 2023554119A JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023537488 A JP2023537488 A JP 2023537488A JP 2023554119 A JP2023554119 A JP 2023554119A
Authority
JP
Japan
Prior art keywords
tcr
cysteine residue
trac
disulfide bond
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537488A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554119A5 (https=
JPWO2022133592A5 (https=
Inventor
エリック エスコバル－カブレラ
リー フライブルガー
ダニエル ティー． パットン
レナード ジー． プレスタ
パトリック ファーバー
チャールズ マイケル スティーブンス
Original Assignee
ザイムワークス ビーシー インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザイムワークス ビーシー インコーポレイテッド filed Critical ザイムワークス ビーシー インコーポレイテッド
Publication of JP2023554119A publication Critical patent/JP2023554119A/ja
Publication of JP2023554119A5 publication Critical patent/JP2023554119A5/ja
Publication of JPWO2022133592A5 publication Critical patent/JPWO2022133592A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023537488A 2020-12-21 2021-12-21 安定化されたｔｃｒコンストラクト及び使用方法 Pending JP2023554119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063128601P 2020-12-21 2020-12-21
US63/128,601 2020-12-21
PCT/CA2021/051855 WO2022133592A1 (en) 2020-12-21 2021-12-21 Stabilized tcr constructs and methods of use

Publications (3)

Publication Number Publication Date
JP2023554119A true JP2023554119A (ja) 2023-12-26
JP2023554119A5 JP2023554119A5 (https=) 2025-01-06
JPWO2022133592A5 JPWO2022133592A5 (https=) 2025-01-06

Family

ID=82157307

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537488A Pending JP2023554119A (ja) 2020-12-21 2021-12-21 安定化されたｔｃｒコンストラクト及び使用方法

Country Status (8)

Country Link
US (1) US20240409604A9 (https=)
EP (1) EP4263593A4 (https=)
JP (1) JP2023554119A (https=)
KR (1) KR20230123474A (https=)
CN (1) CN116648256A (https=)
AU (1) AU2021408160A1 (https=)
CA (1) CA3167637A1 (https=)
WO (1) WO2022133592A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
WO2025140554A1 (en) * 2023-12-29 2025-07-03 Shanghai Epimab Biotherapeutics Co., Ltd. Fusion proteins and uses thereof
CN118108833B (zh) * 2024-03-12 2025-05-02 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用
WO2025214470A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 包含t细胞受体恒定区的蛋白质及其医药用途
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019536437A (ja) * 2016-10-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
US20200283524A1 (en) * 2017-09-22 2020-09-10 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018337142B2 (en) * 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
KR20210020873A (ko) * 2018-04-05 2021-02-24 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
AU2019249209A1 (en) * 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019536437A (ja) * 2016-10-03 2019-12-19 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
US20200283524A1 (en) * 2017-09-22 2020-09-10 WuXi Biologics Ireland Limited Novel bispecific polypeptide complexes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KNIES D. ET AL., ONCOTARGET, vol. 7, JPN6026003233, 2016, pages 21199 - 21221, ISSN: 0005784450 *

Also Published As

Publication number Publication date
US20240052009A1 (en) 2024-02-15
KR20230123474A (ko) 2023-08-23
CA3167637A1 (en) 2022-06-30
WO2022133592A1 (en) 2022-06-30
AU2021408160A1 (en) 2023-06-29
EP4263593A1 (en) 2023-10-25
US20240409604A9 (en) 2024-12-12
EP4263593A4 (en) 2025-05-07
CN116648256A (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
JP2023554119A (ja) 安定化されたｔｃｒコンストラクト及び使用方法
JP7410143B2 (ja) 二重特異性抗体及びその用途
US11584794B2 (en) Bispecific heterodimeric fusion proteins containing IL-15-IL-15Ralpha Fc-fusion proteins and immune checkpoint antibody fragments
US11851466B2 (en) Targeted IL-12 heterodimeric Fc-fusion proteins
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
CN109715663B (zh) 结合生长抑素受体2的异源二聚抗体
US10253091B2 (en) Antibody constant region variant
EP2409991B1 (en) Antibody constant region variant
JP6441079B2 (ja) 二重特異性抗体分子
KR102590061B1 (ko) 유전자 조작 Fc 작제물에 관한 조성물 및 방법
KR20210069641A (ko) IL-12 이종이량체 Fc-융합 단백질
US20190352362A1 (en) LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
CA3131016A1 (en) Multifunctional molecules that bind to calreticulin and uses thereof
US20220010015A1 (en) Antibodies binding to cd3
TW202400642A (zh) 抗ＣＤ２８ｘ抗ＰＳＭＡ抗體
TW202317632A (zh) 已活化肝臟星狀細胞（ｈｓｃ）之耗竭及其用途
JP2025542327A (ja) 新規抗ｇｐｒｃ５ｄ抗体
TW202346337A (zh) Ilt3及cd3結合劑以及其使用方法
CA3149939A1 (en) Proteins comprising t-cell receptor constant domains
CN118451097A (zh) 新型il27受体激动剂及其使用方法
KR20250173599A (ko) 항-cd28 조성물
EP4572779A1 (en) Multi-domain binding molecules
KR20240067092A (ko) 항-klb 항체 및 용도
TW202525853A (zh) 抗ｃｄ２０ｘ抗ｃｄ２８組合療法
HK40099262A (zh) 稳定化的tcr构建体及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241219

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260129